


Prophylactic use of antibiotics for sexually transmitted infections: awareness and use among HIV PrEP users in Belgium

Thibaut Vanbaelen ^{1,2}, Thijs Reyniers ², Anke Rotsaert,²
Bea Vuylsteke ², Eric Florence,¹ Chris Kenyon ¹,
Irith De Baetselier¹

Doxycycline prophylaxis has been shown to reduce the incidence of chlamydia and syphilis infections in various studies, but researchers are worried about increasing antimicrobial resistance (AMR).¹ Although not currently recommended, STI prophylaxis has been reported in high-risk men who have sex with men, with proportions ranging from 2% to 10%.² We assessed the awareness and use of STI prophylaxis among HIV pre-exposure prophylaxis users in Belgium in a nested cross-sectional online survey in December 2021 and January 2022. Participants were recruited through social media, HIV reference centres and social/sexual networking applications. A total of 187 participants completed the survey. The median age was 46 years (IQR 38–53). The majority were born in Belgium (161/187, 86.1%) and identified themselves as male (183/187, 97.9%). Fifty-four participants (28.9%) had ever heard of STI prophylaxis, 21 (11.3%) knew someone who used it and 6 (3.2%) reported having used STI

prophylaxis themselves. Three users reported taking it only after sex and three both before and after sex. Two had used doxycycline, one azithromycin, one amoxicillin and antibiotic was unknown in two cases. Two participants reported having taken STI prophylaxis in the previous month, two in the previous 1–6 months and two >12 months ago. Two participants had obtained these antibiotics through an HIV/STI clinic, one from a sex partner and three reported using leftovers. Although the use of STI prophylaxis was limited in our sample, a substantial proportion of participants were aware of STI prophylaxis or knew persons using it, suggesting that this phenomenon may be more common than initially thought. Another concern is that some antibiotics with a high propensity to induce AMR or no efficacy in reducing the occurrence of bacterial STIs were used. Sensitisation of patients and healthcare providers is needed, as well as further research on the net benefits and risks of STI prophylaxis.

¹Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

²Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium

Correspondence to Dr Thibaut Vanbaelen, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerpen, Belgium; tvnbaelen@itg.be

Handling editor Jonathan Ross

Contributors TV, IDB, AR, BV and TR contributed to the study concept and design. TV performed the data analysis. TV drafted the manuscript. All authors critically revised the manuscript and approved the final version for publication.

Funding This research was funded by Research Foundation—Flanders as an SBO project (S004919N).

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study was approved by Institutional Review Board from the Institute of Tropical Medicine, Antwerp, Belgium (IRB 1380/20). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; internally peer reviewed.



OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Vanbaelen T, Reyniers T, Rotsaert A, *et al.* *Sex Transm Infect* 2022;**98**:625. Published Online First 27 July 2022

Sex Transm Infect 2022;**98**:625. doi:10.1136/sextrans-2022-055511

ORCID iDs

Thibaut Vanbaelen <http://orcid.org/0000-0002-5541-6041>

Thijs Reyniers <http://orcid.org/0000-0003-3756-921X>

Bea Vuylsteke <http://orcid.org/0000-0003-0514-4372>

Chris Kenyon <http://orcid.org/0000-0002-2557-8998>

REFERENCES

- Grant JS, Stafylis C, Celum C, *et al.* Doxycycline prophylaxis for bacterial sexually transmitted infections. *Clin Infect Dis* 2020;**70**:1247–53.
- Kohli M, Medland N, Fifer H, *et al.* BASHH updated position statement on doxycycline as prophylaxis for sexually transmitted infections. *Sex Transm Infect* 2022;**98**:235–6.